Thermo Fisher Scientific
Thermo Fisher Scientific is a globally renowned leader in the scientific solutions and healthcare sectors, maintaining a central and dominant position within the oligonucleotide synthesis market. The company offers a comprehensive portfolio that spans all necessary components for nucleic acid research, including advanced oligonucleotide synthesis equipment, high-quality reagents, custom synthesis services, and diagnostic assays. As one of the prevailing members of this market, Thermo Fisher Scientific is committed to continuous innovation and boasts a world-class R&D division. Their solutions are leveraged by researchers globally to accelerate drug discovery, diagnostics development, and fundamental biological research. They specialize in custom large-scale oligonucleotide synthesis and advanced technologies that support cutting-edge applications in genomics, gene editing, and RNA-based therapies, including an agreement with the University of Sheffield for development of advanced workflows for mRNA and oligonucleotide product characterization. By providing an integrated infrastructure and extensive product line, Thermo Fisher Scientific enables the development of personalized medicine and remains a key global provider of scientific and technological solutions.
Latest Market Research Report on Oligonucleotide Synthesis Download PDF Brochure Now
Integrated DNA Technologies (IDT)
Integrated DNA Technologies, Inc. (IDT), a subsidiary of Danaher Corporation, is a globally recognized leader specializing in the design, manufacture, and distribution of high-quality synthetic nucleic acids. Founded in 1987 and headquartered in Coralville, Iowa, IDT has become a preferred partner for custom oligonucleotide synthesis, particularly in the realm of nucleic acid therapeutics and next-generation sequencing, due to its focus on precision and rapid turnaround times. The company’s industry-leading position is sustained by its proprietary synthesis platforms, including the in-house design, manufacture, and calibration of its DNA synthesizers and the in-house formulation of key synthesis reagents. This vertical integration allows for superior quality control and the ability to produce longer oligos with better sequence fidelity than competitors. IDT’s offerings include DNA and RNA oligonucleotides, probes, and primers for a vast array of molecular biology applications, such as qPCR, CRISPR-Cas9 systems, and gene editing, supporting the ever-changing needs of molecular bench scientists and pharmaceutical developers.
Agilent Technologies
Agilent Technologies, Inc. is a global leader in analytical instrumentation and laboratory systems, with a core strategy centered on integrating advanced technologies into its platforms for life sciences, diagnostics, and applied chemical markets. Within the oligonucleotide synthesis market, Agilent provides a comprehensive offering spanning instruments, reagents, and services. The company is renowned for its state-of-the-art instruments, which range from high-precision synthesizers to advanced analytical systems, which are essential for research, diagnostic, and therapeutic applications of synthetic nucleic acids. Agilent’s solutions are designed to address the critical need for higher throughput, enhanced reproducibility, and precise sample handling in modern research. A key focus is on empowering researchers with reliable, high-performance microfluidic tools and a robust laboratory infrastructure to achieve breakthrough discoveries, underscored by recent investments, such as a $725 million expansion in its manufacturing capacity for nucleic acid-based therapeutics.
Merck KGaA
Merck KGaA, a German multinational science and technology company marketed and recognized globally as Merck, is a major player in the oligonucleotide synthesis industry, primarily through its Life Sciences business segment, which includes Sigma-Aldrich. The company provides a significant range of molecular biology supplies, prominently featuring oligonucleotide synthesis tools and high-quality reagents for diverse research and genetic applications. Merck’s portfolio includes DNA and RNA oligos, predesigned primers, and qPCR probes essential for various research and diagnostic purposes such such as PCR, cloning, next-generation sequencing, and CRISPR. With a strong global presence and an extensive distribution network inherited from Sigma-Aldrich, Merck ensures reliable supply chain management for its customers. Moreover, the company is strategically expanding its oligonucleotide manufacturing capabilities through acquisitions, such as Exelead in 2022, to support its involvement in the high-growth area of lipid nanoparticle and oligonucleotide therapeutics development.
Eurofins Scientific
Eurofins Scientific is a Luxembourg-based international group of laboratories providing a comprehensive range of analytical testing and pharmaceutical services, and it holds a strong position in the oligonucleotide synthesis market through its Eurofins Genomics brand. The company is recognized for chemically manufacturing and selling high-quality synthetic DNA and RNA (oligos), with a dedicated focus on advancing diagnostics and research. Eurofins Genomics is a historical innovator in the field, claiming to be the first company to perform 100% Quality Control on all its oligos. Their services include custom synthesis, NGS oligos, long oligos, and various purification options, all processed using highly automated technologies in high-throughput production facilities. Furthermore, they operate cGMP-compliant facilities for manufacturing regulatory-grade oligos, offering full-process traceability and custom documentation, which strengthens their global footprint and improves accessibility for clients across academic and commercial projects.
Danaher Corporation
Danaher Corporation is a diversified global science and technology conglomerate that is consistently ranked as a leading player in the oligonucleotide synthesis market, largely due to its strategic positioning through its subsidiary brands, most notably Integrated DNA Technologies (IDT). Danaher actively drives the adoption of oligonucleotide technologies across various scientific and clinical applications by offering a broad, integrated DNA/RNA portfolio that spans from research-grade to GMP-grade supply. Their technology solutions and robust market presence are essential in delivering scale, quality, and fast turnaround times for diagnostics, therapeutics, and synthetic biology. By focusing on integrating advanced synthesis technologies, automation, and analytics across its various life sciences and diagnostics segments, Danaher provides the necessary technological infrastructure to support next-generation precision medicine and the development of oligonucleotide-based drugs.
Cytiva (formerly GE Healthcare)
Cytiva, which was formed from the life sciences division of GE Healthcare, maintains a significant and historical presence in the oligonucleotide synthesis market. The company specializes in providing the necessary tools and systems for high-throughput oligonucleotide synthesis and process optimization, empowering manufacturers in both research and commercial settings. Cytiva’s expertise is critical in enabling large-scale and efficient production of synthetic nucleic acids. Through its technology platforms and systems, it supports drug discovery and therapeutic development, as evidenced by its agreement with CordenPharma International for an end-to-end oligonucleotide-based drug discovery solution. Cytiva plays a vital role by providing specialized instruments and components that ensure the scalability and quality required for oligonucleotide manufacturing, solidifying its position as a key enabler in the global life sciences and pharmaceutical supply chain.
Ajinomoto Bio-Pharma Services
Ajinomoto Bio-Pharma Services is a key Contract Development and Manufacturing Organization (CDMO) that provides high-quality, custom oligonucleotide services. As part of the global Ajinomoto group, which has expertise in amino acid-based products, this US-based organization leverages its innovative AJIPHASE synthesis technology to offer services ranging from early-stage R&D to large-scale commercial GMP manufacturing. The company is strategically positioned to serve the global nucleic acid drug market, supporting the development of therapeutic molecules. Ajinomoto Bio-Pharma Services has actively invested in expanding its oligonucleotide manufacturing capabilities and is also focused on internal innovation, such as the development of a highly functional artificial RNA ligase enzyme, which helps to fuel a new, quickly emerging generation of treatments and diagnostics based on oligonucleotide chemistry.
Maravai LifeSciences (TriLink BioTechnologies)
Maravai LifeSciences, through its subsidiary TriLink BioTechnologies, is a prominent and rapidly expanding leader in the oligonucleotide synthesis and nucleic acid production market. TriLink specializes in scalable, high-purity custom chemical oligo synthesis built to perform for advanced research and therapeutic applications, boasting over 25 years of experience. The company provides a wide range of services, including long RNA oligos, gRNAs, siRNAs, and aptamers, supported by an extensive catalog of over 400 modifications and in-house custom chemistry services. Maravai is strategically expanding its GMP oligo and modified-nucleotide capacity, notably leveraging its proprietary CleanCap mRNA technology. This focus on high-quality, clinical-grade oligo and mRNA/siRNA programs, backed by its ISO 9001 and ICH Q7-compliant US facility, positions Maravai LifeSciences as a vital partner for pharmaceutical and diagnostic developers.
Ionis Pharmaceuticals
Ionis Pharmaceuticals, Inc. is a pioneering biopharmaceutical company and a central figure in the therapeutic segment of the oligonucleotide market, specializing in the development of antisense oligonucleotide (ASO) drugs. Founded in 1989, Ionis revolutionized gene regulation by creating a novel drug discovery platform that generates a pipeline of ASO therapeutics. The company’s focus is on using this antisense technology to treat a wide range of serious diseases. With a robust pipeline of over 40 antisense drugs and a history of significant technology transfers and collaborations with major pharmaceutical companies, Ionis drives the demand and sets the quality standards for clinical-grade oligo manufacturing. Its leadership in the development and commercialization of this class of drugs fundamentally shapes the requirements and advancements in the large-scale, high-purity oligonucleotide synthesis industry.
Latest Market Research Report on Oligonucleotide Synthesis Download PDF Brochure Now